ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
NPS Pharmaceuticals has regained worldwide rights to recombinant human parathyroid hormone 1-84 and to Gattex, a therapy for patients with short bowel syndrome, from Japan’s Takeda Pharmaceutical. Takeda will receive NPS stock valued at $50 million and milestone payments over one year of up to $30 million. NPS had licensed rights to the compounds outside North America in 2004 and 2007, respectively, to Nycomed. Takeda acquired Nycomed in 2011.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter